Novo Nordisk, maker of Ozempic and Wegovy sues two pharmacies for ‘selling impure drugs’
Ozempic and Wegovy, announced on Thursday that it had filed lawsuits against two pharmacies after tests found the products to be tainted. This is Novo Nordisk's latest legal action against pharmacies gaining popularity.
Novo Nordisk said that the lawsuits have been filed against Florida-based Wells Pharmacy Network and Brooksville Pharmaceuticals.
It has been alleged that both provided compounded drugs that included up to 33% impure semaglutide, the generic name for Wegovy and Ozempic.
According to Novo Nordisk, the unidentified contaminants «may pose safety risks» to consumers, including «possibly serious and life-threatening reactions» like anaphylaxis. It also alleged that Brooksville Pharmaceuticals was selling products that were 19% less effective than what was shown.
According to Novo Nordisk, Wells Pharmacy Network has been «falsely and misleadingly» advertising an unapproved compounded drug that purports to contain BPC-157, a substance that the Food and Drug Administration has banned.
According to the lawsuits filed by Novo Nordisk, BPC-157's label purports that it can “provide many benefits for the human body,” leading consumers to believe that the drug has FDA approval.
